Skip to main content

CORRECTION article

Front. Pharmacol., 05 January 2022
Sec. Ethnopharmacology

Corrigendum: COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis

Zewen Chu&#x;Zewen Chu1Xin Shi&#x;Xin Shi2Gaoyang ChenGaoyang Chen2Xuejun HeXuejun He2Yayun QianYayun Qian1Haibo WangHaibo Wang1Li TaoLi Tao3Yanqing LiuYanqing Liu1Wei Jiang
Wei Jiang3*Jue Chen,
Jue Chen1,2*
  • 1Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
  • 2Department of Oncology, The Second People’s Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China
  • 3College of Environmental Science and Engineering, Marine Science and Technology Institute, Yangzhou University, Yangzhou, China

A Corrigendum on
COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis

by Chu, Z., Shi, X., Chen, G., He, X., Qian, Y., Wang, H., Tao, L., Liu, Y., Jiang, W., and Chen, J. (2021). Front. Pharmacol. 12:619732. doi:10.3389/fphar.2021.619732

In the original article, there was a mistake in Figure 2, Figure 4, and Figure 6 as published. The mistake was induced by using PPT software to import all experimental pictures of each group of drugs at one time during picture sorting. In the subsequent ranking of representative pictures, the pictures of individual concentrations were mixed with those of other concentrations. The corrected Figure 2, Figure 4, and Figure 6 appear below.

FIGURE 2
www.frontiersin.org

FIGURE 2. COE inhibits VM formation both in vitro and in vivo. (A) COE inhibits networks and loops formed by HepG2 and MHCC97-H cells on Matrigel surface ×200. Scale bar, 20 µm. (B), comparison of networks among negative control, COE (20, 40, and 80 μg/ml) treated cells and positive control (sorafenib 5 µM) treated cells. Relative numbers derived from Image J. Two-tailed t-test. Error bars show s.e.m. ∗, p < 0.05, ∗∗, p < 0.01, vs. negative control. (C), COE inhibits VM formation in MHCC97-H xenograft. Left: CD31-PAS staining in MHCC97-H tumors. Right: statistics for VM vessels, number indicates quantity of VM vessels per mm2. ×400, scale bar, 50 µm, ∗∗, p < 0.01, versus negative control.

FIGURE 4
www.frontiersin.org

FIGURE 4. Evaluation of targets derived from proteomics analysis. (A), RT-PCR assay for the most significantly down-regulated genes. ∗, p < 0.05, ∗∗, p < 0.01, versus negative control. Ctrl, negative control (PBS), Two-tailed t-test. (B), upper panel, cell invasion assay, scale bar, 20 μm lower panel, VM formation assay, scale bar, 50 µm NVP, NVP-BHG712. (C), Western blotting analysis on the expression of VM related protein biomarkers after blocking EphA2.

FIGURE 6
www.frontiersin.org

FIGURE 6. COE inhibits invasion and VM associated protein biomarkers via inhibiting EphA2 in HCC cells. (A), COE decreases HepG2 and MHCC97-H cell invasion. Left: representative image for transwell assay, right: histogram of invaded cells. ×200, 20 µm. (B), COE and NVP inhibit VM formation of HepG2 and MHCC97-H on matrigel. HUVECs used as the control. (C), Western blot analysis on the change of expression of VM related proteins after COE treatment.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: vasculogenesis mimicry, hepatocel lular carcinoma, EphA2, protemics, cancer treatment

Citation: Chu Z, Shi X, Chen G, He X, Qian Y, Wang H, Tao L, Liu Y, Jiang W and Chen J (2022) Corrigendum: COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis. Front. Pharmacol. 12:831941. doi: 10.3389/fphar.2021.831941

Received: 09 December 2021; Accepted: 14 December 2021;
Published: 05 January 2022.

Edited and reviewed by:

Luca Rastrelli, University of Salerno, Italy

Copyright © 2022 Chu, Shi, Chen, He, Qian, Wang, Tao, Liu, Jiang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wei Jiang, weijiang@yzu.edu.cn; Jue Chen, 1019924551@qq.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.